Biotechnology Industry Organization (BIO) Urges Congress to Prioritize Patient Safety and Biomedical Innovation in Pathway for Follow-On Biologics

WASHINGTON--(BUSINESS WIRE)--A diverse group of patient advocacy organizations has joined the Biotechnology Industry Organization (BIO) in urging that patient safety and continued biomedical innovation stand as critical components of any statutory effort to establish a pathway to approve development of follow-on biologics. The patient groups and leaders of BIO’s Emerging Companies Section (ECS) Governing Body sent letters this week to members of the House Energy and Commerce Committee in advance of today’s hearing on follow-on biologics in the Subcommittee on Health.
MORE ON THIS TOPIC